<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04430712</url>
  </required_header>
  <id_info>
    <org_study_id>2020P000361</org_study_id>
    <nct_id>NCT04430712</nct_id>
  </id_info>
  <brief_title>Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume</brief_title>
  <official_title>Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume in Patients With Non-Small Cell Lung Cancer: A Case-Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators plan to test whether Immune Checkpoint Inhibitor (ICI) treatment&#xD;
      leads to an accelerated progression of atherosclerosis in patients with non-small cell lung&#xD;
      cancer. Atherosclerosis is an immune-mediated inflammatory disease and these same checkpoints&#xD;
      being targeted for cancer are critical negative regulators of atherosclerosis in animal and&#xD;
      cellular models. Aortic plaque progression will be compared between cases (on ICI) and&#xD;
      controls from pre-ICI to post-ICI among patients with non-small cell lung cancer. Groups will&#xD;
      be matched for age, cancer type and stage and cardiovascular risk factors. Traditional&#xD;
      markers of cardiovascular (CVD) risk and cancer-specific factors (ICI mono- and combination&#xD;
      therapy, number of cycles, occurrence of immune-related adverse events, chest radiation,&#xD;
      steroid use) will be associated with the change in aortic plaque volume.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in aortic plaque volume</measure>
    <time_frame>Three years</time_frame>
    <description>The change of plaque burden after starting ICIs will be calculated and compared with the pre-ICI study. The change in plaque burden in controls will be calculated and compared from two studies at a similar median interval as ICI cases.</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-small cell lung cancer from a single tertiary care center in the United&#xD;
        States.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cases:&#xD;
&#xD;
          -  Subjects with non-small cell lung cancer treated with Immune Checkpoint Inhibitors.&#xD;
&#xD;
          -  Available contrast enhanced CT scans of the chest both immediately pre-ICI (&lt; 1 month)&#xD;
             and latest follow-up.&#xD;
&#xD;
        Controls:&#xD;
&#xD;
          -  Subjects with non-small cell lung cancer, age, cancer stage and cardiovascular risk&#xD;
             factor matched to cases.&#xD;
&#xD;
          -  Available contrast enhanced CT scan of the chest at two time-points at a similar&#xD;
             interval between scans as the cases.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tomas G. Neilan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

